Market

FDA Approves Journavx: A New Non-Opioid Solution for Acute Pain
Research & Development FDA Approves Journavx: A New Non-Opioid Solution for Acute Pain

On Thursday, the Food and Drug Administration approved Journavx, a highly anticipated non-opioid pain medication developed by Vertex Pharmaceuticals, marking a significant milestone in the effort to shift pain treatment away from opioids. This new drug has been initially approved to treat acute

Navigating Funding Challenges for Behavioral Health Startups
Tech & Innovation Navigating Funding Challenges for Behavioral Health Startups

The current landscape of behavioral health startups is marked by a competitive funding environment. Companies in this sector face numerous challenges as they strive to secure capital, navigate investment trends, and differentiate themselves in a crowded market. This article explores these dynamics,

Can Teladoc Health Overcome Financial Woes and Drive Future Growth?
Tech & Innovation Can Teladoc Health Overcome Financial Woes and Drive Future Growth?

Teladoc Health, a prominent player in the telehealth market, has been navigating a challenging financial landscape while striving to maintain its expansive reach and drive future growth. With 93 million members and 10,000 customers, the company has a significant presence in the virtual healthcare

Digital Health Market Poised for Significant Growth by 2034
Tech & Innovation Digital Health Market Poised for Significant Growth by 2034

The global digital health industry is on the brink of a remarkable growth trajectory, with its market value expected to surge from USD 8,131.3 million in 2024 to USD 16,603.7 million by 2034. This substantial rise represents a compound annual growth rate (CAGR) of 7.4% over the forecast period,

How is Mexico Leading the EHR Market with Digital Innovation?
Tech & Innovation How is Mexico Leading the EHR Market with Digital Innovation?

Mexico is at the forefront of a digital health revolution, particularly in the realm of Electronic Health Records (EHR). This rapid transformation is driven by a combination of government initiatives, regulatory changes, and a growing demand for modernized healthcare systems. The country’s

MilliporeSigma Acquires HUB Organoids, Advancing Drug Development
Biotech & Bioprocessing MilliporeSigma Acquires HUB Organoids, Advancing Drug Development

MilliporeSigma, the Life Science business of Merck KGaA in the U.S. and Canada, has announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). This acquisition marks a significant step forward in enhancing their 2D and 3D cell culture portfolio with the innovative technology of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later